Curated headlines, concise summaries, and trusted source links — built for students, educators, and exam aspirants tracking what matters.
Stay updated with educational news, policy shifts, and global developments from reputable RSS sources — filtered by category, region, and topic.
Each brief links to the original publisher. Shalyam adds summaries and context to help you read faster and remember more.
Domain: Pharmacology: Understanding Drug Actions and Interactions
×
Current affairs articles
Geopolitics
40,000 bottles of eye drops across the US recalled over issues with sterility of product
The Guardian – World
· Europe
Prestige Brand Holdings has voluntarily recalled a batch of its Clear Eyes eye drops after FDA alertNearly 40,000 bottles of eye drops are being pulled from st…
Can a drug help prevent trauma? Study with mice suggests so
Deutsche Welle (DW) – World
· Europe
Researchers in Munich and Stockholm blocked the lifelong social cost of early adversity in mice with a single compound. The catch: it only worked when given du…
Global pharma giants turn to Chinese biotech to tap innovation, valuation growth
South China Morning Post – World
· China
Global pharmaceutical giants are doubling down on investing in China’s fast-growing biotech companies given the sector’s huge room for valuation growth, accord…
Peptris is using AI to find drug candidates to shorten the time it takes for laboratory validation
Your Story
· India
The Bengaluru-based company builds models that generate molecules and predict how they will behave, and has licensed its lead candidate to a US developer.
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
The Guardian – World
· Europe
Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updatesBritain’s biggest dr…
Best known as Viagra, the erectile dysfunction drug sildenafil started off as a treatment for reduced blood flow but soon saw its value spike after its other e…
RenaissThera is designing oral drugs for obesity and type 2 diabetes
Your Story
· India
The Bengaluru-based company uses AI-led discovery to search for small molecules that act on the same receptors as injectable GLP-1 drugs, aiming for a cheaper …
The opioid-like compound, which is found in kratom, can cause brutal withdrawal symptoms and will soon be a controlled substance. Some users tell WIRED it has …
An FDA Panel Just Endorsed These Unproven Peptides
Wired
· Global
Outside experts—some with a vested interest in peptides—recommended adding a number of the amino acids to the FDA’s bulks list, including the “Wolverine stack”…
How AI helps scientists design the next generation of medicines
MIT Technology Review
· Global
Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a signif…
‘Systemic leap’: China’s drug innovation push yields bumper crop
South China Morning Post – World
· China
Domestically produced novel drugs accounted for more than 80 per cent of market approvals in China in the first half of the year, reflecting a “leap” in the qu…
Why the West has an uphill task challenging China in pharmaceutical ingredients
South China Morning Post – World
· China
From rare earth elements to commercial drones, Washington has become all too familiar with the strongest weapons in Beijing’s manufacturing arsenal – the mater…
China bans pet anaesthetic tiletamine after waves of young people vape drug
South China Morning Post – World
· China
China has banned tiletamine, a common veterinary anaesthetic, after its recreational inhalation among young people escalated sharply.
Since July 1, the compoun…
‘Life-saving’ drug for people with opioid dependency to be pulled from Australia by end of year
The Guardian – World
· Europe
Exclusive: Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administrationGet our breaking news email…
China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
South China Morning Post – World
· China
Home-grown innovative drugs make up most of the medicines China’s drug regulator has approved for sale so far this year, underscoring the country’s biotech boo…
After 5 deaths in Kota, Rajasthan bans childbirth drug TOCIN ,sample fails potency test
Times of India – World
· India
Rajasthan's Drug Control Department has banned TOCIN (Oxytocin Injection 5 ml) manufactured by Jackson Laboratories Pvt Ltd after a sample failed quality tests…
A new agreement aims to tackle the drug shortages that have plagued the bloc. Among other things, it would make it easier to use public funds to support the pr…
Medicines watchdog to investigate UK peptide clinics over health claims
The Guardian – World
· Europe
Exclusive: Guardian investigation finds several clinics making potentially unlawful claims about benefits of unregulated therapiesWhat are peptides, are they s…
China’s ‘pig semen eyedrop’ may help treat Alzheimer’s: scientist in Australia
South China Morning Post – World
· China
An innovative therapy using pig semen-derived exosomes, engineered into eye drops capable of penetrating deep into retinal tissue, may hold the key to breachin…
- Rupali is a journalist with 20 years of experience in consumer sectors, now focusing on pharmaceuticals, healthcare, and consumer trends.
- Financial calcu…
Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline
South China Morning Post – World
· China
CK Life Sciences, a unit of Li Ka-shing-backed CK Group, plans to bring its cancer vaccine candidates to mainland China through a “fast track” channel as Beiji…
A study published in Science Advances by Baylor College of Medicine has uncovered a hidden brain pathway that helps explain how metformin lowers blood sugar, o…
A technologist’s journey into shortening drug discovery, shaped by OpenAI tools
Your Story
· India
Drug discovery has long been defined by time, cost, and repeated failure. Medvolt AI is using OpenAI-enabled intelligence to reduce experimental cycles and mov…
China’s weight-loss drug makers take on global giants as Novo Nordisk patent expires
South China Morning Post – World
· China
At least 10 weight-loss injections and oral pills are lining up for regulatory approval in China, in a market projected to reach about US$14 billion by 2030.
N…
Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
South China Morning Post – World
· China
US biopharmaceutical company Gilead Sciences agreed to buy Ouro Medicines, which is developing an antibody-based medicine for autoimmune diseases licensed from…
Global drug giants double down on China amid trend to build self-reliant supply chains
South China Morning Post – World
· China
AstraZeneca said it would establish drug manufacturing facilities in Guangzhou and Shanghai as well as a separate innovation centre in Shanghai, joining a grou…
India’s weight-loss price war begins as semaglutide patent expires
South China Morning Post – World
· China
Namita Joshi made a New Year’s resolution in January to tackle one of her long-standing problems: being overweight. A key part of her slimming journey is her w…
Ozempic Is About to Go Generic in India, China and Canada
The New York Times – World
· US
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for …
Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain
South China Morning Post – World
· China
Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, …
Hong Kong woman, 30, arrested over illegal sale of slimming injection
South China Morning Post – World
· China
Hong Kong authorities have arrested a 30-year-old woman on suspicion of illegally selling poisons and unregistered pharmaceutical products, after an undercover…
Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals
South China Morning Post – World
· China
Hong Kong-listed mainland Chinese pharmaceutical companies are on track to deliver full-year profits, as surging drug sales and lucrative out-licensing deals w…
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
The Guardian – World
· Europe
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectationsBusiness live – latest updatesThe owner of Wegovy and Ozemp…
At Shalyam, our Current Affairs section curates headlines and brief excerpts
from publicly available RSS feeds of reputed publications. Each item links back to the original source
for full reading, ensuring that the rights of the respective publishers are respected under the
Indian Copyright Act, 1957.
We do not reproduce full articles; instead, we provide short snippets for reference along with our own
commentary, insights, and fact-based analysis. All copyrights remain with the original publishers,
and proper attribution is maintained for every article displayed.
FAQ
Answers to the questions you might have in mind
Frequently asked questions
What is Shalyam Current Affairs?+
A curated feed of educational and general news with summaries and links to trusted sources, sorted by publication date.
How often is news updated?+
RSS feeds are fetched regularly and AI summaries may be generated for selected articles when enabled.
Can I filter news by region or category?+
Yes. Use category, region, and tag filters on the current affairs page.
40,000 bottles of eye drops across the US recalled over issues with sterility of product
Source: The Guardian – World
·
- Prestige Brand Holdings recalls 39,060 bottles of Clear Eyes eye drops due to sterility concerns, per FDA.
- FDA classifies recall as Class II (moderate risk), with potential for temporary health issues.
- Recall targets 15ml bottles with lot code 2552A and expiration date 30 Sept 2027.
- Consumers advised to stop using, return bottles for refund, and consult healthcare providers.
Can a drug help prevent trauma? Study with mice suggests so
Source: Deutsche Welle (DW) – World
·
- Researchers blocked lifelong social harm from early adversity in mice using SAFit2, a compound targeting FKBP51, only effective when administered during trauma.
- Early hardship increased FKBP51, keeping stress responses active; the drug reversed this, normalizing social behavior and brain gene activity.
- Study focused on male mice; SAFit2 remains untested in humans, with clinical use likely decades away, requiring pre-trauma intervention.
- Targeting FKBP51 could address stress disorders at their root, contrasting with current treatments like SSRIs, which address symptoms rather than causes.
Global pharma giants turn to Chinese biotech to tap innovation, valuation growth
Source: South China Morning Post – World
·
- Foreign investments boost Chinese biotech growth, per Citic Securities, as global pharma giants target China’s high-growth sector.
- Global Health Summit highlights pharma firms doubling down on China’s biotech for valuation potential and innovation.
- AstraZeneca and CSPC form joint venture (49% stake) to focus on manufacturing and global product expansion.
- Mölnlycke and Zhende Medical partner to combine portfolios and co-develop medical products via joint venture.
Peptris is using AI to find drug candidates to shorten the time it takes for laboratory validation
Source: Your Story
·
- **Peptris Technologies** (founded 2019 in Bengaluru) uses AI to generate novel molecules and predict drug properties, streamlining drug discovery by narrowing chemical candidates.
- Focuses on rare diseases, inflammation, oncology, and women’s health, repurposing existing compounds to accelerate development with preclinical safety data.
- Raised Rs 70 crore in Series A to expand AI tech, build partnerships, and advance PEPR-124 (Phase 2-ready for Duchenne muscular dystrophy) toward clinical trials.
- PEPR-124 has U.S. orphan drug designation for rare diseases but hasn’t completed clinical trials, competing with Indian AI-driven drug discovery firms.
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
Source: The Guardian – World
·
- AstraZeneca and Bristol Myers Squibb (BMS) are in talks for a $400bn merger, creating the world’s fourth-largest drugmaker by market value.
- AstraZeneca’s shares dropped 7%, while BMS rose 8%, reflecting investor uncertainty and regulatory challenges.
- Overlapping oncology portfolios and BMS’s declining sales pose hurdles, while analysts question the merger’s strategic value.
- A deal could boost AstraZeneca’s U.S. presence but risks regulatory scrutiny and may not resolve long-term growth concerns.
Viagra shows potential against cancer spread
Source: South China Morning Post – World
·
- Tel Aviv scientists found sildenafil (Viagra) may curb cancer metastasis via a new mechanism linked to blood dilatation.
- Sildenafil limits cancer cells' cholesterol use, essential for metastasis, by blocking their ability to form new membranes.
- Cholesterol is vital for cancer cells to migrate and invade organs, so limiting access hinders metastasis.
- Combining sildenafil with statins could boost its potential to limit cancer spread by targeting cholesterol pathways.
RenaissThera is designing oral drugs for obesity and type 2 diabetes
Source: Your Story
·
- **RenaissThera** (founded 2023 in Bengaluru) develops affordable therapies for cardio-metabolic diseases like diabetes and obesity using small molecules targeting GLP-1 and GIP receptors.
- The company leverages AI, machine learning, and collaborations (e.g., VedTechBio) to design molecules, with seven oral drug candidates in discovery stage.
- Raised seed funding (under $500k total) to advance lead candidates toward Investigational New Drug readiness and human trials.
- Aims to create an affordable, orally administered obesity drug that differs from existing injectable treatments, targeting global accessibility.
7-OH Users Are Stockpiling Ahead of a DEA Ban
Source: Wired
·
- Cam, a 36-year-old with severe post-accident pain, turned to 7-OH kratom after oxycodone failed, finding it effective for pain relief and daily activities.
- DEA plans to classify 7-OH as Schedule I, banning its sale and use, citing public health risks and unregulated supplement safety concerns.
- Users face financial strain and withdrawal risks, with debates over kratom’s legal status and potential opioid relapse if access is restricted.
- Online communities provide tapering advice, highlighting growing reliance on 7-OH for chronic pain management amid regulatory uncertainty.
An FDA Panel Just Endorsed These Unproven Peptides
Source: Wired
·
- FDA advisory panel narrowly recommends reclassifying four peptides (BPC-157, TB-500, KPV, MOTs-C) for compounding, with three approved and one split.
- Peptides, touted for health benefits, face safety concerns due to lack of evidence, while FDA scientists oppose their compounding.
- Gray market thrives due to unregulated sales, with China/India as major suppliers, raising risks of illicit substances.
- Panel’s approval may not eliminate the gray market, sparking debate over public confusion and ethical concerns about legalization.
How AI helps scientists design the next generation of medicines
Source: MIT Technology Review
·
- AI accelerates biologic drug discovery, cutting decades-long timelines and reducing failure rates through computational prioritization and rapid iteration.
- AI enables complex multi-target therapies and "drugging the undruggable," optimizing potency, stability, and manufacturability for previously unreachable disease targets.
- AstraZeneca integrates AI with robotics in a "lab of the future" to create closed-loop systems, generating vast datasets for real-time model refinement and faster drug development.
- The ultimate goal is "de novo" AI-designed proteins, fully engineered from scratch to meet clinical candidate criteria, driven by advanced models and high-quality training data.
US regulators to weigh controversial peptides backed by RFK Jr
Source: Al Jazeera – News
·
- FDA reviews seven peptides for pharmacy availability amid rising demand, citing safety and efficacy concerns due to limited clinical trials.
- Peptides, promoted for weight loss, aging, and pain, face scrutiny over quality and effectiveness, with no approved FDA drugs in this category.
- Advisory committee includes members tied to peptide businesses, raising ethics concerns despite HHS claims of rigorous vetting.
- Social media, influencers, and endorsements drive demand, despite FDA warnings about unregulated use and lack of evidence.
The Great Peptide Cash Grab Has Begun
Source: Wired
·
- FDA may reclassify peptides for compounding, reversing 2023 restrictions, after industry lobbying and pending July 23-24 review.
- Telehealth firms and pharmacies are preparing to offer custom peptide mixes, investing in testing and protocols.
- Clinics like Amanecia Health are prescribing peptides despite lack of FDA approval, driven by social media demand.
- Gray-market peptides are widely available online, prompting warnings against unregulated sales and early market entry.
‘Systemic leap’: China’s drug innovation push yields bumper crop
Source: South China Morning Post – World
·
- Domestic drugs accounted for 80% of China's first-half approvals, showing growth in pharmaceutical innovation.
- 38 innovative drugs approved, 31 home-grown, per Ministry of Industry and Information Technology.
- Satri-cel, a CAR-T therapy, became first CAR-T treatment for solid tumors, approved for late-stage stomach cancer.
- BCI system for spinal injuries approved, restoring hand motor function, developed by Neuracle Medical Technology.
Why the West has an uphill task challenging China in pharmaceutical ingredients
Source: South China Morning Post – World
·
- China's pharmaceutical input production has surged, boosting its global market share and raising U.S. concerns about strategic leverage.
- U.S. think tanks warn China’s dominance in APIs and KSMs could mirror its rare earths influence, risking geopolitical dependency.
- China supplies 40% of global APIs and 41% of U.S.-approved drug KSMs, alarming Washington over supply chain vulnerabilities.
- U.S. and allies are urged to strengthen medical supply chains and reduce reliance on China to mitigate dependency risks.
China bans pet anaesthetic tiletamine after waves of young people vape drug
Source: South China Morning Post – World
·
Here are four clear bullet points summarizing the article:
• China has banned tiletamine, a veterinary anaesthetic, after its recreational inhalation among young people escalated sharply.
• Tiletamine's chemical structure is similar to ketamine, and it was mainly used for surgical anesthesia in pets like cats and dogs.
• The substance became popular in entertainment venues such as billiard halls, discos, nightclubs, and bars in China.
• In Shenyang alone, 1,605 individuals were investigated and educated for tiletamine abuse from November 2025 to early January 2026.
‘Life-saving’ drug for people with opioid dependency to be pulled from Australia by end of year
Source: The Guardian – World
·
Here are four clear bullet points summarizing the article:
• US pharmaceutical company Indivior will stop marketing and selling the long-acting injectable prescription opioid Sublocade in Australia by the end of 2022, citing a lack of commercial viability.
• Sublocade was added to the PBS in 2020 and is considered a significant advance in treatment for people living with opioid dependency due to its monthly injection administration.
• The move has raised concerns among doctors and pharmacists, who are warning of potential disruptions to patient care and the possibility of more drugs being pulled from the market in response to global market pressures.
• The Australian government cannot compel companies to continue supply, but is urging Indivior to work with authorities and experts to ensure an orderly transition and minimize disruption to patients.
China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom
Source: South China Morning Post – World
·
Here are four clear bullet points summarizing the news article:
• China's regulator overhauled its approval process to accelerate the path to market for domestic innovative drugs.
• The country approved 76 innovative drugs last year, a significant increase from 48 in 2021.
• Domestic firms dominated China's drug approvals, with state media reporting an uptick in spending and out-licensing deals.
• China has elevated the pharmaceutical sector to a national economic growth engine for the first time in this year's government work report.
After 5 deaths in Kota, Rajasthan bans childbirth drug TOCIN ,sample fails potency test
Source: Times of India – World
·
Here are the four clear bullet points summarizing the news article:
• Rajasthan government has banned TOCIN oxytocin injection after a sample failed potency tests.
• The drug is used to induce labor and control bleeding, but its potency was found to be compromised.
• As many as 3,500 vials of the injection were seized in Kota.
• The ban aims to ensure patient safety and prevent any adverse effects from using the compromised drug.
EU negotiators agree new rules on vital medicines
Source: Deutsche Welle (DW) – World
·
Here are four clear bullet points summarizing the article:
• The European Union has reached an agreement on new rules aimed at reducing drug shortages and boosting supply chains for essential medicines.
• The rules will make it easier to use public funds to support the production of critical medicines, prioritizing those manufactured in Europe during public procurement.
• The agreement also allows for collaborative purchasing among EU countries to acquire important medicines, particularly for rare illnesses where market demand is lacking.
• The new rules aim to address supply chain vulnerabilities, including bottlenecks in active ingredient sourcing and reliance on a few countries for production, as seen during the COVID-19 pandemic.
Medicines watchdog to investigate UK peptide clinics over health claims
Source: The Guardian – World
·
- UK clinics face MHRA investigation for unlawful claims about unregulated peptide therapies, which lack human evidence.
- Peptides are marketed for anti-ageing and recovery, but most studies are pre-clinical, with no large trials on long-term safety.
- Clinics charge £350–£450/month for experimental peptides, despite labeling them "research only" and warning of risks.
- MHRA warns against medicinal claims, while clinics argue they provide balanced info but acknowledge limited evidence and risks.
China’s ‘pig semen eyedrop’ may help treat Alzheimer’s: scientist in Australia
Source: South China Morning Post – World
·
- New therapy uses exosomes from pig semen to cross blood-brain barrier, published in *Science Advances* (March 27) for dementia treatment.
- Exosomes, natural nanoparticles from pig semen, safely deliver drugs through biological barriers.
- Zhao Chunxia, Adelaide researcher, highlights technique’s potential to treat Alzheimer’s and other conditions via blood-brain barrier.
- Technology could improve drug delivery across other barriers, expanding treatment options for various diseases.
FDA Approves Eli Lilly’s GLP-1 Pill
Source: Wired
·
- FDA approved Eli Lilly’s GLP-1 obesity pill Foundayo, the second weight-loss GLP-1 pill, with flexible dosing and no food restrictions.
- Foundayo competes with Novo Nordisk’s Wegovy pill, offering easier administration and potential market expansion for GLP-1 drugs.
- Clinical trials showed Foundayo led to 27 lbs weight loss over 18 months, outperforming placebo, though no direct comparison with Wegovy’s pill exists.
- FDA expedited approval via a pilot program, addressing shortages and improving access for patients seeking non-injectable GLP-1 options.
India’s biologics dream hits Chinese wall
Source: Times of India – World
·
- Rupali is a journalist with 20 years of experience in consumer sectors, now focusing on pharmaceuticals, healthcare, and consumer trends.
- Financial calculators estimate loan installments, SIP returns, PPF/FD maturity, NPS pensions, and mutual fund future values.
- Tools help users calculate investment returns, interest, and corpus for retirement and long-term savings.
- Mutual Fund Calculator aids in forecasting investment growth based on contributions and market conditions.
Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline
Source: South China Morning Post – World
·
- Sequencio, CK Life’s HK unit, advances 20 cancer vaccine projects via China’s accelerated regulatory pathway for faster human trials.
- China’s IITs allow drug makers to generate clinical data 1.5–2 years faster than conventional processes.
- Dr. Toh emphasizes early entry and rapid approval to boost revenue and secure market advantage.
- First-to-market advantage is critical for generating revenue and staying ahead in competitive drug development.
Diabetic drug metformin found to act on brain
Source: Times of India – World
·
- Anuja Jaiswal is a Senior Assistant Editor at The Times of India with 18 years in narrative journalism, specializing in health and heritage reporting.
- She simplifies complex health information for engaging, reader-friendly narratives.
- Her heritage reporting combines thorough research with captivating storytelling.
- Gained diverse on-ground experience across Chandigarh, Chhattisgarh, and West UP.
A technologist’s journey into shortening drug discovery, shaped by OpenAI tools
Source: Your Story
·
- Medvolt AI uses AI to cut preclinical drug development time and cost by reducing experimental iterations.
- Combines AI with scientists in real-time collaboration, leveraging generative chemistry and simulations.
- Integrates OpenAI tools for data analysis, content creation, and experimental planning.
- Collaborates with ACTREC on breast cancer research, streamlining planning and testing processes.
China’s weight-loss drug makers take on global giants as Novo Nordisk patent expires
Source: South China Morning Post – World
·
- Novo Nordisk’s semaglutide patent expired in China, enabling local firms to compete in the weight-loss market.
- Hengrui Medicine and Innovent Biologics applied for approvals, with Innovent’s mazdutide becoming China’s first homegrown obesity drug.
- Trial data showed Hengrui’s ribupatide (17.7% weight loss) and Innovent’s mazdutide (18.55% loss) outperformed semaglutide.
- Patent expiry opens avenues for Chinese firms to challenge global giants in the lucrative obesity treatment sector.
Rights to antibody drug from China’s Keymed change hands in Gilead acquisition of Ouro
Source: South China Morning Post – World
·
- Keymed may receive up to $320 million from Gilead's $2.18B acquisition of Ouro, which licenses its autoimmune treatment CM336.
- Ouro holds exclusive rights to develop CM336 globally except mainland China, Hong Kong, Macau, and Taiwan.
- Keymed secured upfront payments, equity stake (15%), and milestone rewards from Ouro's sale to Gilead.
- Deal aims to accelerate CM336’s global development as a potential best-in-class T-cell-engaging antibody for autoimmune diseases.
Global drug giants double down on China amid trend to build self-reliant supply chains
Source: South China Morning Post – World
·
- Multinationals are enhancing self-reliant supply chains in China to mitigate trade risks, driven by its manufacturing, cost, and supply chain advantages.
- AstraZeneca committed $15B to China’s drug market by 2030, leveraging local capabilities for long-term growth and technical expertise.
- AstraZeneca will build a radioconjugate drug plant in Guangzhou’s tech zone for prostate cancer treatments in Asia-Pacific.
- The firm plans cell therapy production in Shanghai’s free-trade zone and an innovation hub at Zhangjiang Hi-Tech Park.
India’s weight-loss price war begins as semaglutide patent expires
Source: South China Morning Post – World
·
- Generic slimming drugs are set to surge in a market where 25% of adults are overweight or obese.
- Namita Joshi uses weekly injections to lose 6kg, improving her mental health and dating prospects.
- Medication costs her ~$322 monthly, with prices dropping further this week.
- Her financial independence allows treatment, despite the high expense and side effects like nausea.
Ozempic Is About to Go Generic in India, China and Canada
Source: The New York Times – World
·
- Novo Nordisk's Ozempic/Wegovy will lose patent protection in India, China, and other populous nations, enabling cheaper generic versions.
- Generics will expand access to a drug previously unaffordable for most, targeting over 800 million obese adults in India and China.
- Generics may increase global usage, as the drugs reduce heart attack and stroke risks, with significant market potential.
- U.S. and Europe will delay generic access until 2030 due to stronger patent protections, unlike other regions.
Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain
Source: South China Morning Post – World
·
- Eli Lilly boosts China operations amid pharma competition, raising total investment to nearly $6 billion.
- Establishes domestic production for oral solid preparations to enhance supply chain.
- Focuses on orforglipron, a first-in-class GLP-1 drug for diabetes and obesity.
- Highlights strategic commitment to China's market growth and future expansion.
Hong Kong woman, 30, arrested over illegal sale of slimming injection
Source: South China Morning Post – World
·
- Hong Kong arrests 30-year-old woman for illegally selling unregistered pharmaceuticals, including a mislabeled Mounjaro injection pen.
- Authorities seized the product via an undercover operation using a tip-off and an instant messaging app transaction.
- Seized item was Eli Lilly’s Mounjaro pen, labeled in Japanese and containing tirzepatide, an anti-obesity drug.
- Woman suspected of selling poisons and unregistered drugs online, violating health regulations.
Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals
Source: South China Morning Post – World
·
- Chinese pharma firms expect profit growth from innovative drugs and licensing deals in 2025.
- Pricing pressures pose domestic challenges but are unlikely to derail earnings from innovative products.
- Macquarie Capital’s Tony Ren highlights strong performance of innovative drugs despite hurdles.
- Domestic challenges persist, but the sector remains optimistic for 2025 earnings resilience.
Wellness peptide craze: Why people are injecting drugs 'not for human consumption'
Source: BBC News – World
·
- Katie injects GHK-Cu (for research only) for skin benefits, ignoring safety warnings, claiming stretch marks are fading.
- Unregulated peptides like GHK-Cu lack safety data, risking immune reactions, contamination, and long-term health risks.
- Social media fuels peptide use for wellness, with claims of muscle growth, recovery, and metabolism, despite unproven efficacy.
- Experts warn unregulated peptide use creates a public health risk, likening it to a "biological gamble" with potential chronic side effects.
Game-Changing Drugs
Source: The New York Times – World
·
- New weight-loss drugs (Ozempic, Wegovy, Mounjaro) are hailed as transformative but have long-term risks.
- They target GLP-1 receptors to aid weight loss, but their long-term effects remain unclear.
- Experts caution about potential unknown consequences, emphasizing the need for further research.
- The drugs have shown rapid weight loss in some users, but guidelines on usage are still evolving.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Source: The Guardian – World
·
- Novo Nordisk’s shares plummeted 16.5% after CagriSema’s clinical trial showed 23% weight loss (vs. 25.5% for tirzepatide), missing non-inferiority goals.
- Analysts criticized the results, calling CagriSema “obsolete” compared to rivals, amid Novo’s sales and profit forecast cuts.
- Novo’s CEO defends the drug, claiming it will be the first amylin-based product with the best weight-loss label, pending higher-dose trials.
- The company seeks regulatory approval in the US, despite disappointing data, hoping to launch CagriSema early next year.
Get Exclusive Insightswith Every Issue
Join Shalyam Newsletter
Stay ahead in education, research, and innovation—straight to your inbox.
Ask us anything – we’ll reply via WhatsApp or Telegram within 24 hours.
We use cookies to run Shalyam and, only if you allow it, to understand how the site is used so we can improve it.
Analytics cookies stay off until you choose Accept analytics; you can change your mind at any time from
"Cookie settings" in the footer.
Privacy policy